Peli BioThermal Expands European Manufacturing Centre

Published: Oct 04, 2017

Extended facilities in France to produce bulk thermal shipper CoolPall™ Vertos to meet growing global demand

Peli BioThermal, the global name in temperature controlled packaging, today announces the expansion of its European manufacturing capabilities in France.

This extension is in response to meet the rising requirements of the worldwide transportation of pharmaceuticals throughout Europe and globally.

David Williams, President of Peli BioThermal, said: “I’m pleased to announce the extension of our production capability in France, to manufacture our single use bulk thermal shipper CoolPall™ Vertos. It is an exciting development and customers will benefit from the consistent quality and processes implemented worldwide.

“These significant changes and investments represent the ongoing efforts that Peli BioThermal is making and are a clear indication of our commitment to our customers, the industry and our global expansion of manufacturing and services.”

This implementation of the additional European manufacturing capabilities complements the company’s expanding existing facilities, providing solutions for customers globally, which included the recent introduction of new service centres in Belgium and Puerto Rico.

The latest European expansion demonstrates the company’s commitment to significant investment to serve customers globally and follows the qualification of production of the company’s reusable Credo Cube™ line of thermal shippers at its facility in the United Kingdom and the expanded manufacturing capability for the single-use Chronos™ Advance, Chronos™ Express and CoolPall™ Vertos product lines to its facility in the United States.

Visit www.pelibiothermal.com to learn more about the wide range of Peli BioThermal products.

Peli BioThermal is a division of Peli Products, S.L.U., which is the European arm of Pelican Products, Inc., which is a portfolio company of Behrman Capital, a private equity investment firm based in New York and San Francisco.

Back to news